Matches in SemOpenAlex for { <https://semopenalex.org/work/W2098840461> ?p ?o ?g. }
- W2098840461 endingPage "673" @default.
- W2098840461 startingPage "663" @default.
- W2098840461 abstract "Introduction: Sorafenib is a multi-tyrosine kinase inhibitor (TKI). Considerable clinical experience has been accumulated since its first Phase III clinical trial in metastatic renal cancer patients in 2007. The management of its early acute toxicity in fit patients is well known. The management of prolonged treatment becomes the new challenge. Areas covered: Using sorafenib as a key word for PubMed search, we review preclinical and clinical data and discuss the pharmacokinetics and pharmacodynamics of sorafenib, its acute and cumulative toxicities and their consequences for patient management. Expert opinion: The systematic multi-disciplinary risk assessment of cancer patients prior to TKI initiation reduces the risks of acute and late toxicity, especially drug–drug interactions and arterial risks. Sarcopenia is now identified as a major risk of severe toxicity. The very diverse clinical pictures of cumulative toxicity must be known. The monitoring of sorafenib systemic exposure is helpful especially in elderly patients. Moreover, at disease progression, it allows distinguishing between underexposure to sorafenib and truly acquired resistance to the drug. The optimal use of sorafenib should allow improving the reported results of flat-dose. Finally, most of this knowledge could be used for the development and optimal use of the other TKIs." @default.
- W2098840461 created "2016-06-24" @default.
- W2098840461 creator A5002331357 @default.
- W2098840461 creator A5010804968 @default.
- W2098840461 creator A5015222370 @default.
- W2098840461 creator A5030130725 @default.
- W2098840461 creator A5039428493 @default.
- W2098840461 creator A5060413020 @default.
- W2098840461 creator A5065121477 @default.
- W2098840461 creator A5086034709 @default.
- W2098840461 creator A5090375155 @default.
- W2098840461 creator A5090828621 @default.
- W2098840461 creator A5091487792 @default.
- W2098840461 creator A5030929356 @default.
- W2098840461 date "2014-04-03" @default.
- W2098840461 modified "2023-10-14" @default.
- W2098840461 title "Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients" @default.
- W2098840461 cites W1596431542 @default.
- W2098840461 cites W1963616402 @default.
- W2098840461 cites W1971837077 @default.
- W2098840461 cites W1972301208 @default.
- W2098840461 cites W1975051553 @default.
- W2098840461 cites W1976228480 @default.
- W2098840461 cites W1979000743 @default.
- W2098840461 cites W1985320798 @default.
- W2098840461 cites W1986069210 @default.
- W2098840461 cites W1992098760 @default.
- W2098840461 cites W1994193851 @default.
- W2098840461 cites W1995690008 @default.
- W2098840461 cites W1996845958 @default.
- W2098840461 cites W1997533142 @default.
- W2098840461 cites W1997567636 @default.
- W2098840461 cites W1999658754 @default.
- W2098840461 cites W1999966467 @default.
- W2098840461 cites W2004362238 @default.
- W2098840461 cites W2006782694 @default.
- W2098840461 cites W2009930854 @default.
- W2098840461 cites W2012072673 @default.
- W2098840461 cites W2014563113 @default.
- W2098840461 cites W2021568546 @default.
- W2098840461 cites W2022286388 @default.
- W2098840461 cites W2023952988 @default.
- W2098840461 cites W2024564431 @default.
- W2098840461 cites W2026392720 @default.
- W2098840461 cites W2033587656 @default.
- W2098840461 cites W2037527490 @default.
- W2098840461 cites W2038827789 @default.
- W2098840461 cites W2038884833 @default.
- W2098840461 cites W2039471613 @default.
- W2098840461 cites W2040189718 @default.
- W2098840461 cites W2041851693 @default.
- W2098840461 cites W2043021219 @default.
- W2098840461 cites W2044481963 @default.
- W2098840461 cites W2053599004 @default.
- W2098840461 cites W2054865212 @default.
- W2098840461 cites W2055294608 @default.
- W2098840461 cites W2058736678 @default.
- W2098840461 cites W2059293297 @default.
- W2098840461 cites W2062625348 @default.
- W2098840461 cites W2067541215 @default.
- W2098840461 cites W2068556039 @default.
- W2098840461 cites W2073788073 @default.
- W2098840461 cites W2076017354 @default.
- W2098840461 cites W2077285193 @default.
- W2098840461 cites W2078025290 @default.
- W2098840461 cites W2093895772 @default.
- W2098840461 cites W2094249509 @default.
- W2098840461 cites W2096057999 @default.
- W2098840461 cites W2097955112 @default.
- W2098840461 cites W2101841728 @default.
- W2098840461 cites W2102942095 @default.
- W2098840461 cites W2103689170 @default.
- W2098840461 cites W2105396478 @default.
- W2098840461 cites W2106366840 @default.
- W2098840461 cites W2108118667 @default.
- W2098840461 cites W2111639514 @default.
- W2098840461 cites W2115125611 @default.
- W2098840461 cites W2122724278 @default.
- W2098840461 cites W2122751925 @default.
- W2098840461 cites W2127385754 @default.
- W2098840461 cites W2127956530 @default.
- W2098840461 cites W2128502566 @default.
- W2098840461 cites W2130207513 @default.
- W2098840461 cites W2130572339 @default.
- W2098840461 cites W2135387190 @default.
- W2098840461 cites W2135400147 @default.
- W2098840461 cites W2135678285 @default.
- W2098840461 cites W2136110110 @default.
- W2098840461 cites W2139817384 @default.
- W2098840461 cites W2143036717 @default.
- W2098840461 cites W2147186814 @default.
- W2098840461 cites W2148802557 @default.
- W2098840461 cites W2150615783 @default.
- W2098840461 cites W2156871508 @default.
- W2098840461 cites W2157076786 @default.
- W2098840461 cites W2157262448 @default.
- W2098840461 cites W2158151049 @default.
- W2098840461 cites W2159687102 @default.